The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...

Pacira BioSciences, Inc.'s stock is up 33%, backed by a new Exparel patent, growth strategies, and market trends. Click here ...

So in the case of NaV1.8, our New England Journal Paper a couple ... I've ever met with type 1 diabetes who doesn't consider the current state to be overwhelming life experience and not in a ...

According to the US Centers for Disease Control and Prevention (CDC), the current wave of opioid overdoses ... The drug is an oral, selective NaV1.8 pain signal inhibitor that is targeted at ...

"We also expect multiple regulatory filings in 2025 coming out of our early-stage portfolio - which includes Kv7 and Nav1.7 candidates that are progressing ... 2023. Based on current operating plans, ...

"We also expect multiple regulatory filings in 2025 coming out of our early-stage portfolio - which includes Kv7 and Nav1.7 candidates that are progressing ... 2023. Based on current operating plans, ...

This drug may reduce the risk of addiction to pain medications by decreasing reliance on opioids to reduce pain.

Levicept chief executive Eliot Forster told pharmaphorum that the company plans to move to subcutaneous administration of LEVI-04 in later-stage development, noting that the current formulation is ...

Designed to be taken orally twice a day, it works by selectively targeting and blocking a specific subset of these sodium channels called NaV1.8, preventing pain signals ... This approach closely ...